Evaluation of platelet parameters and neutrophil/lymphocyte ratio during omalizumab treatment in patients with severe chronic spontaneous urticaria

Background/aim Spontaneous wheals and/or angioedema lasting longer than six weeks are described as chronic spontaneous urticaria (CSU). Omalizumab is used for the treatment of antihistamine-resistant CSU. The neutrophil–lymphocyte ratio (NLR), platelet– lymphocyte ratio (PLR), mean platelet volume (MPV), and platelet distribution width (PDW) are considered important indicators of inflammation and platelet activation in chronic diseases. We aimed to determine the NLR, PLR, MPV, and PDW levels in patients with CSU compared with healthy controls. We also aimed to investigate the effects of omalizumab therapy on these parameters in CSU patients. Materials and methods This hospital-based, retrospective study included 143 patients with CSU and 132 healthy controls with a mean age of 40.0 ± 13.17 and 42.0 ± 16.34, respectively. Patients with equal or higher-than-baseline UAS scores at week 12 of omalizumab treatment were considered nonresponders, others were considered responders. We analyzed the neutrophils, lymphocytes, platelet counts, NLR, PLR, MPV, and PDW before, during, and after omalizumab treatment and compared the results with those of healthy controls. Results CSU patients presented higher baseline MPV (P = 0.035) and lower baseline PDW values (P < 0.001) than healthy controls. There were statistically significant increases in the MPV (P < 0.001), MPV/platelet count (P = 0.005), and PDW (P = 0.003) and there was a statistically significant decrease in the NLR (P = 0.018) during omalizumab treatment. The percent increase of MPV was low in nonresponders (P = 0.009). Nonresponders had lower PDW values than responders (P = 0.040). Conclusion The increase in the MPV and PDW may be due to platelet activation during omalizumab treatment. The decrease in the NLR may be regarded as an antiinflammatory effect of omalizumab. The effect of omalizumab on platelet and inflammatory markers may be used to discriminate the responders from nonresponders.

[1]  M. Maurer,et al.  The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change , 2018, Allergy. European Journal of Allergy and Clinical Immunology.

[2]  M. Maurer,et al.  Increased IgE levels are linked to faster relapse in patients with omalizumab-discontinued chronic spontaneous urticaria. , 2017, The Journal of allergy and clinical immunology.

[3]  P. Burchardt,et al.  The Role of Hematological Indices in Patients with Acute Coronary Syndrome , 2017, Disease markers.

[4]  D. Avcı,et al.  Can we use the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and mean platelet volume values for the diagnosis of anterior uveitis in patients with Behcet’s disease? , 2017, Therapeutics and clinical risk management.

[5]  K. Rothman,et al.  Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma , 2017, The Journal of allergy and clinical immunology.

[6]  L. Garcia,et al.  Neutrophil lymphocyte ratio in peripheral vascular disease: a review , 2016, Expert review of cardiovascular therapy.

[7]  Kemal Özyurt,et al.  Adverse Reaction to Omalizumab in Patients with Chronic Urticaria: Flare Up or Ineffectiveness? , 2016, Iranian journal of allergy, asthma, and immunology.

[8]  I. Altunay,et al.  Serum C-Reactive Protein, Neutrophil-Lymphocyte Ratio and Uric Acid Levels in Chronic Spontaneous Urticaria , 2016 .

[9]  A. Aras,et al.  Neutrophil–Lymphocyte Ratio Connected to Treatment Options and Inflammation Markers of Ankylosing Spondylitis , 2015, Journal of clinical laboratory analysis.

[10]  Michihiro Hide,et al.  The EAACI/GA 2 LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update , 2015 .

[11]  M. Maurer,et al.  The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. , 2015, The Journal of allergy and clinical immunology.

[12]  J. Prajapati,et al.  Association of High Density Lipoprotein with Platelet to Lymphocyte and Neutrophil to Lymphocyte Ratios in Coronary Artery Disease Patients , 2014, Journal of lipids.

[13]  T. Zuberbier,et al.  The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. , 2014, Allergy.

[14]  J. Kasperski,et al.  The Association between Platelet Count and Acute Phase Response in Chronic Spontaneous Urticaria , 2014, BioMed research international.

[15]  M. Rajappa,et al.  Platelet activation in chronic urticaria and its correlation with disease severity , 2014, Platelets.

[16]  T. Casale,et al.  Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. , 2013, The New England journal of medicine.

[17]  R. Gorczynski,et al.  Clinical course and side effects of anti-IgE monoclonal antibody in patients with severe persistent asthma. , 2013 .

[18]  A. Hartzema,et al.  Assessing the association between omalizumab and arteriothrombotic events through spontaneous adverse event reporting , 2012, Journal of asthma and allergy.

[19]  M. Leshno,et al.  Chronic urticaria and autoimmunity: associations found in a large population study. , 2012, The Journal of allergy and clinical immunology.

[20]  J. Mishal,et al.  Clinical and laboratory features of antihistamine-resistant chronic idiopathic urticaria. , 2011, Allergy and asthma proceedings.

[21]  G. Kitas,et al.  Mean platelet volume: a link between thrombosis and inflammation? , 2011, Current pharmaceutical design.

[22]  T. Zuberbier,et al.  Epidemiology of urticaria: a representative cross‐sectional population survey , 2010, Clinical and experimental dermatology.

[23]  J. Mishal,et al.  Increased Mean Platelet Volume and C-Reactive Protein Levels in Patients With Chronic Urticaria With a Positive Autologous Serum Skin Test , 2010, The American journal of the medical sciences.

[24]  S. Spector,et al.  Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic / Spontaneous Urticaria Who Remain Symptomatic on H 1 Antihistamines : A Randomized , Placebo-Controlled Study , 2010 .

[25]  E. Gounari,et al.  Platelet distribution width: a simple, practical and specific marker of activation of coagulation. , 2010, Hippokratia.

[26]  G. Kitas,et al.  Mean platelet volume in patients with rheumatoid arthritis: the effect of anti-TNF-alpha therapy , 2010, Rheumatology International.

[27]  D. Ledford Omalizumab: overview of pharmacology and efficacy in asthma , 2009, Expert opinion on biological therapy.

[28]  S. Holgate,et al.  Safety and tolerability of omalizumab , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[29]  H. Schünemann,et al.  EAACI/GA2LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria , 2006, Allergy.

[30]  T. Kawamoto,et al.  Relationship between Hemostatic Factors and the Platelet Index in Patients with Ischemic Heart Disease , 2007, Pathophysiology of Haemostasis and Thrombosis.

[31]  J. Brittenden,et al.  The role of platelets in peripheral vascular disease. , 2003, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.